Literature DB >> 3025219

Topoisomerase II: A specific marker for cell proliferation.

M M Heck, W C Earnshaw.   

Abstract

We have used an antibody probe to measure the levels of topoisomerase II in several transformed and developmentally regulated normal cell types. Transformed cells contain roughly 1 X 10(6) copies of the enzyme. During erythropoiesis in chicken embryos the enzyme level drops from 7.8 X 10(4) copies per erythroblast to less than 300 copies per erythrocyte concomitant with the cessation of mitosis in the blood. Cultured myoblasts also lose topoisomerase II upon fusion into nonproliferating myotubes. When peripheral blood lymphocytes (which lack detectable topoisomerase II) commence proliferation, they express topoisomerase II de novo. Appearance of the enzyme exactly parallels the onset of DNA replication. These results suggest that topoisomerase II is not required for transcription in higher eukaryotes, but that it may function during DNA replication. Furthermore, topoisomerase II is a sensitive and specific marker for proliferating cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3025219      PMCID: PMC2114590          DOI: 10.1083/jcb.103.6.2569

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  50 in total

1.  Isolation and characterisation of a strain carrying a conditional lethal mutation in the cou gene of Escherichia coli K12.

Authors:  E Orr; N F Fairweather; I B Holland; R H Pritchard
Journal:  Mol Gen Genet       Date:  1979

2.  Chromosomal loop anchorage of the kappa immunoglobulin gene occurs next to the enhancer in a region containing topoisomerase II sites.

Authors:  P N Cockerill; W T Garrard
Journal:  Cell       Date:  1986-01-31       Impact factor: 41.582

3.  Metaphase chromosome structure: the role of nonhistone proteins.

Authors:  U K Laemmli; S M Cheng; K W Adolph; J R Paulson; J A Brown; W R Baumbach
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1978

4.  Cell fractionation and arrangement on fibers, beads, and surfaces.

Authors:  G M Edelman; U Rutishauser; C F Millette
Journal:  Proc Natl Acad Sci U S A       Date:  1971-09       Impact factor: 11.205

5.  Three human chromosomal autoantigens are recognized by sera from patients with anti-centromere antibodies.

Authors:  W Earnshaw; B Bordwell; C Marino; N Rothfield
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

6.  Skeletal myoblasts in culture.

Authors:  I R Konigsberg
Journal:  Methods Enzymol       Date:  1979       Impact factor: 1.600

7.  In situ localization of DNA topoisomerase II, a major polypeptide component of the Drosophila nuclear matrix fraction.

Authors:  M Berrios; N Osheroff; P A Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

8.  Mutagenic responses of thirteen anticancer drugs on mutation induction at multiple genetic loci and on sister chromatid exchanges in Chinese hamster ovary cells.

Authors:  B Singh; R S Gupta
Journal:  Cancer Res       Date:  1983-02       Impact factor: 12.701

9.  Cloning of yeast TOP1, the gene encoding DNA topoisomerase I, and construction of mutants defective in both DNA topoisomerase I and DNA topoisomerase II.

Authors:  T Goto; J C Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

10.  Isolation of type I and II DNA topoisomerase mutants from fission yeast: single and double mutants show different phenotypes in cell growth and chromatin organization.

Authors:  T Uemura; M Yanagida
Journal:  EMBO J       Date:  1984-08       Impact factor: 11.598

View more
  89 in total

1.  Cloning and characterization of a cDNA encoding topoisomerase II in pea and analysis of its expression in relation to cell proliferation.

Authors:  M K Reddy; S Nair; K K Tewari; Y Mudgil; B S Yadav; S K Sopory
Journal:  Plant Mol Biol       Date:  1999-09       Impact factor: 4.076

2.  Antitrypanosomal activity of fluoroquinolones.

Authors:  E Nenortas; C Burri; T A Shapiro
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

Review 3.  Topoisomerase II: its functions and phosphorylation.

Authors:  S M Gasser; R Walter; Q Dang; M E Cardenas
Journal:  Antonie Van Leeuwenhoek       Date:  1992-08       Impact factor: 2.271

4.  The geometry of DNA supercoils modulates topoisomerase-mediated DNA cleavage and enzyme response to anticancer drugs.

Authors:  A Kathleen McClendon; Neil Osheroff
Journal:  Biochemistry       Date:  2006-03-07       Impact factor: 3.162

5.  Biological indices in the assessment of breast cancer.

Authors:  A S Leong; A K Lee
Journal:  Clin Mol Pathol       Date:  1995-10

6.  Tyrosine 656 in topoisomerase IIβ is important for the catalytic activity of the enzyme: Identification based on artifactual +80-Da modification at this site.

Authors:  Adrian G Grozav; Belinda B Willard; Toshiyuki Kozuki; Kenichi Chikamori; Marius A Micluta; Andrei-Jose Petrescu; Michael Kinter; Ram Ganapathi; Mahrukh K Ganapathi
Journal:  Proteomics       Date:  2011-01-31       Impact factor: 3.984

7.  Potential utility of an expression array signature for predicting anthracycline responsiveness or resistance.

Authors:  Michael F Press; Michael A Gordon; Dennis J Slamon
Journal:  J Clin Oncol       Date:  2011-12-27       Impact factor: 44.544

8.  The sequence-specific nuclear matrix binding factor F6 is a chicken GATA-like protein.

Authors:  Y S Vassetzky; C V De Moura Gallo; A N Bogdanova; S V Razin; K Scherrer
Journal:  Mol Gen Genet       Date:  1993-04

9.  Doxorubicin activity is enhanced by hyperthermia in a model of ex vivo vascular perfusion of human colon carcinoma.

Authors:  Pierluigi Pilati; Simone Mocellin; Carlo R Rossi; Romano Scalerta; Rita Alaggio; Luciano Giacomelli; Cristina Geroni; Donato Nitti; Mario Lise
Journal:  World J Surg       Date:  2003-05-13       Impact factor: 3.352

10.  Novel carbamate analogues of amsacrine with activity against non-cycling murine and human tumour cells.

Authors:  G J Finlay; K M Holdaway; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.